Tecentriq® (atezolizumab) – New indication
October 18, 2016 – Genentech announced the FDA approval of Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy.
Download PDF
